These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 19593505)

  • 1. Pathology role in adjuvant setting.
    Reiner-Concin A
    Cancer Treat Res; 2009; 151():41-61. PubMed ID: 19593505
    [No Abstract]   [Full Text] [Related]  

  • 2. [Immunohistochemical research on breast cancer cell proliferation and hormonal receptor status with special emphasis on HER-2/neu expression].
    Ohlinger R; Steffen SM; Oellig F; Köhler G; Schwesinger G; Lorenz G
    Zentralbl Gynakol; 2002 Oct; 124(10):473-7. PubMed ID: 12712389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
    J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of oestrogen and progesterone receptors, and c-erbB-2 in carcinoma of the breast in Trinidadian women.
    Rao AV; Mohammed WA; Ragoonanan C; Omo-Igbinomwanhia NE
    West Indian Med J; 2002 Mar; 51(1):4-9. PubMed ID: 12089875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Biological features of breast cancer in patients under 35].
    Damenia AO; Turkevich EA; Semiglazov VF; Kochetova IA; Gurbanov SS; Bit-Sava EM; Efimenko AV
    Vopr Onkol; 2007; 53(6):674-6. PubMed ID: 18416136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Current aspects in histopathological assessment of breast cancer].
    Sastre X
    Bull Cancer; 1997 Jan; 84(1):65-8. PubMed ID: 9180862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Occult multicentric breast cancer].
    Vtorushin SV; Zab'ialova MV; Glushchenko SA; Perel'muter VM; Slonimskaia EM
    Vopr Onkol; 2009; 55(1):38-41. PubMed ID: 19435197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of clinical, pathological status, hormone receptor and C-erbB-2 oncoprotein in breast cancer patients.
    Aryandono T; Harijadi ; Ghozali A
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():600-6. PubMed ID: 10895217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High prevalence of HER-2/neu overexpression among Iranian women with breast cancer: true or false?
    Saatee S; Afrakhteh M; Sadrolhefazi B
    Breast J; 2006; 12(5):499-501. PubMed ID: 16958978
    [No Abstract]   [Full Text] [Related]  

  • 10. Surgical specimen can be replaced by core samples in assessment of ER, PR and HER-2 for invasive breast cancer.
    Sutela A; Vanninen R; Sudah M; Berg M; Kiviniemi V; Rummukainen J; Kataja V; Kärjä V
    Acta Oncol; 2008; 47(1):38-46. PubMed ID: 17851859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous analysis of c-erbB-2 expression and DNA content in breast cancer using flow cytometry.
    Stål O; Sullivan S; Sun XF; Wingren S; Nordenskjöld B
    Cytometry; 1994 Jun; 16(2):160-8. PubMed ID: 7924685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is immunohistochemistry less sensitive than quantitative reverse transcriptase polymerase chain reaction for hormone receptor status determination in breast cancer?
    Arnould L; Coudert B; Fumoleau P
    J Clin Oncol; 2009 Jun; 27(16):2733; author reply 2734-5. PubMed ID: 19380432
    [No Abstract]   [Full Text] [Related]  

  • 13. Cancer is heterogeneous.
    Guinebretiere JM
    J Clin Oncol; 2009 Jun; 27(16):2732; author reply 2734-5. PubMed ID: 19380436
    [No Abstract]   [Full Text] [Related]  

  • 14. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
    Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
    Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors for breast cancer and their use in the clinical setting.
    Kapoor A; Vogel VG
    Expert Rev Anticancer Ther; 2005 Apr; 5(2):269-81. PubMed ID: 15877524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of C-erbB-2 and hormone receptors' status in human benign and malignant breast lesions.
    Goussia A; Agnantis NJ; Athanassiadou S; Stefanou D
    Anticancer Res; 1995; 15(5B):2313-8. PubMed ID: 8572645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer.
    Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
    Anticancer Res; 1997; 17(2B):1417-23. PubMed ID: 9137508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The role of definition of receptor status in the prognosis and the choice of adequate treatment tactics of breast tumors].
    Abuladze TZ; Nemsadze GG; Gersamiia GK
    Georgian Med News; 2006 Aug; (137):22-4. PubMed ID: 16980736
    [No Abstract]   [Full Text] [Related]  

  • 19. Simultaneous immunohistochemical and biochemical hormone receptor assessment in breast cancer provides complementary prognostic information.
    Biesterfeld S; Schröder W; Steinhagen G; Koch R; Veuskens U; Schmitz FJ; Handt S; Böcking A
    Anticancer Res; 1997; 17(6D):4723-9. PubMed ID: 9494596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Commentary: hormone receptor testing in breast cancer: a distress signal from Canada.
    Allred DC
    Oncologist; 2008 Nov; 13(11):1134-6. PubMed ID: 18987048
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.